Expression profile analysis of hippocampal CA1 pyramidal neurons in aged Ts65Dn mice, a model of Down syndrome (DS) and Alzheimer’s disease (AD)

Brain Structure and Function

Volumn 220, Issue 5, 2015, Pages 2983-2996

  Alldred, Melissa J ^a,b   Lee, Sang Han ^a   Petkova, Eva ^a,b   Ginsberg, Stephen D ^a,b  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Alzheimer s disease; BDNF; Down syndrome; Glutamatergic neurotransmission; Hippocampus; Laser capture microdissection; Murine model; Neurotrophin

Indexed keywords

4 AMINOBUTYRIC ACID; AMYLIN; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BINDING PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CASPASE 8; CATHEPSIN H; CATHEPSIN X; CILIARY NEUROTROPHIC FACTOR; COLONY STIMULATING FACTOR 1; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; CYCLIN DEPENDENT KINASE 5; CYCLIN G1; ESTROGEN RECEPTOR BETA; GLUTAMATE DEHYDROGENASE; GLUTAMATE RECEPTOR; NERVE GROWTH FACTOR BETA SUBUNIT; NEUROTROPHIN 3; NEUROTROPHIN 4; NEUROTROPHIN RECEPTOR; NEUROTROPHIN RECEPTOR P75; NICOTINIC RECEPTOR; PRION PROTEIN; SERUM AMYLOID P;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLINERGIC NERVE CELL; CONTROLLED STUDY; DOWN REGULATION; DOWN SYNDROME; FOREBRAIN; GENE EXPRESSION PROFILING; GENOTYPE; HIPPOCAMPAL CA1 REGION; MICROARRAY ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PYRAMIDAL NERVE CELL; UPREGULATION; AGING; ANIMAL; BASAL FOREBRAIN; DISEASE MODEL; FEMALE; GENETICS; LEARNING; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE;

AGING; ALZHEIMER DISEASE; ANIMALS; BASAL FOREBRAIN; CA1 REGION, HIPPOCAMPAL; CHOLINERGIC NEURONS; DISEASE MODELS, ANIMAL; DOWN SYNDROME; FEMALE; LEARNING; MALE; MICE, TRANSGENIC; PYRAMIDAL CELLS;

EID: 84940575866     PISSN: 18632653     EISSN: 18632661     Source Type: Journal    
DOI: 10.1007/s00429-014-0839-0     Document Type: Article

References (99)

1. Akeson E, Lambert J (2001) Ts65Dn–localization of the translocation breakpoint and trisomic gene content in a mouse model for Down syndrome. Cytogenet Cell Genet 276:270–276
2. Alldred MJ, Che S, Ginsberg SD (2008) Terminal continuation (TC) RNA amplification enables expression profiling using minute RNA input obtained from mouse brain. Int J Mol Sci 9:2091–2104
3. Alldred MJ, Che S, Ginsberg SD (2009) Terminal continuation (TC) RNA amplification without second strand synthesis. J Neurosci Methods 177:381–385
4. Alldred MJ, Duff KE, Ginsberg SD (2012) Microarray analysis of CA1 pyramidal neurons in a mouse model of tauopathy reveals progressive synaptic dysfunction. Neurobiol Dis 45:751–762
5. Applied Biosystems (2008) Guide to performing relative quantitation of gene expression using real-time quantitative PCR. Gene Expr 2009:1–60
6. Belichenko PV, Masliah E, Kleschevnikov AM et al (2004) Synaptic structural abnormalities in the Ts65Dn mouse model of Down syndrome. J Comp Neurol 480:281–298
7. Belichenko NP, Belichenko PV, Kleschevnikov AM et al (2009) The “Down syndrome critical region” is sufficient in the mouse model to confer behavioral, neurophysiological, and synaptic phenotypes characteristic of Down syndrome. J Neurosci 29:5938–5948
8. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 57:289–300
9. Boada R, Hutaff-Lee C, Schrader A et al (2012) Antagonism of NMDA receptors as a potential treatment for Down syndrome: a pilot randomized controlled trial. Transl Psychiatry 2:e141
10. Carter TL, Rissman RA, Mishizen-Eberz AJ et al (2004) Differential preservation of AMPA receptor subunits in the hippocampi of Alzheimer’s disease patients according to Braak stage. Exp Neurol 187:299–309
11. Cataldo AM, Peterhoff CM, Troncoso JC et al (2000) Endocytic pathway abnormalities precede amyloid β deposition in sporadic Alzheimer’s disease and Down syndrome. Am J Pathol 157:277–286
12. Cataldo AM, Petanceska S, Peterhoff CM et al (2003) App gene dosage modulates endosomal abnormalities of Alzheimer’s disease in a segmental trisomy 16 mouse model of Down syndrome. J Neurosci 23:6788–6792
13. Chao MV (2003) Retrograde transport redux. Neuron 39:1–2
14. Chapman R, Hesketh L (2000) Behavioral phenotype of individuals with Down syndrome. Ment Retard Dev Disabil Res Rev 95:84–95
15. Che S, Ginsberg SD (2004) Amplification of RNA transcripts using terminal continuation. Lab Invest 84:131–137
16. Chen Z, Simmons MS, Perry RT et al (2008) Genetic association of neurotrophic tyrosine kinase receptor type 2 (NTRK2) with Alzheimer’s disease. Am J Med Genet B Neuropsychiatr Genet 147:363–369
17. Chen Y, Dyakin VV, Branch CA et al (2009) In vivo MRI identifies cholinergic circuitry deficits in a Down syndrome model. Neurobiol Aging 30:1453–1465
18. Chong S-A, Benilova I, Shaban H et al (2011) Synaptic dysfunction in hippocampus of transgenic mouse models of Alzheimer’s disease: a multi-electrode array study. Neurobiol Dis 44:284–291
19. Cooper JD, Salehi A, Delcroix JD et al (2001) Failed retrograde transport of NGF in a mouse model of Down’s syndrome: reversal of cholinergic neurodegenerative phenotypes following NGF infusion. Proc Natl Acad Sci USA 98:10439–10444
20. Costa ACS, Scott-McKean JJ, Stasko MR (2008) Acute injections of the NMDA receptor antagonist memantine rescue performance deficits of the Ts65Dn mouse model of Down syndrome on a fear conditioning test. Neuropsychopharmacology 33:1624–1632
21. Counts SE, Che S, Ginsberg SD, Mufson EJ (2011) Gender differences in neurotrophin and glutamate receptor expression in cholinergic nucleus basalis neurons during the progression of Alzheimer’s disease. J Chem Neuroanat 42:111–117
22. Counts SE, Alldred MJ, Che S et al (2014) Synaptic gene dysregulation within hippocampal CA1 pyramidal neurons in mild cognitive impairment. Neuropharmacology 79:172–179
23. Dang V, Medina B, Das D et al (2014) Formoterol, a long-acting β2 adrenergic agonist, improves cognitive function and promotes dendritic complexity in a mouse model of Down syndrome. Biol Psychiatry 75:179–188
24. Danysz W, Parsons CG (2012) Alzheimer’s disease, β-amyloid, glutamate, NMDA receptors and memantine—searching for the connections. Br J Pharmacol 167:324–352
25. Das I, Reeves RH (2011) The use of mouse models to understand and improve cognitive deficits in Down syndrome. Dis Model Mech 4:596–606
26. Davisson M, Schmidt C, Reeves RH et al (1993) Segmental trisomy as a mouse model for Down syndrome. Prog Clin Biol Res 384:117–133
27. Efron B (2007) Correlation and large-scale simultaneous significance testing. J Am Stat Assoc 102:93–103
28. Esbensen AJ (2010) Health conditions associated with aging and end of life of adults with Down syndrome. Int Rev Res Ment Retard 39:107–126
29. Escorihuela RM, Fernández-Teruel A, Vallina IF et al (1995) A behavioral assessment of Ts65Dn mice: a putative Down syndrome model. Neurosci Lett 199:143–146
30. Gardiner K, Fortna A, Bechtel L, Davisson MT (2003) Mouse models of Down syndrome: how useful can they be? Comparison of the gene content of human chromosome 21 with orthologous mouse genomic regions. Gene 318:137–147
31. Ginsberg SD (2005a) Glutamatergic neurotransmission expression profiling in the mouse hippocampus after perforant-path transection. Am J Geriatr Pyschiatry 13:1052–1061
32. Ginsberg SD (2005b) RNA amplification strategies for small sample populations. Methods 37:229–237
33. Ginsberg SD (2007) Expression profile analysis of brain aging. In: Riddle DR (ed) Brain aging: models, methods and mechanisms. CRC Press, New York, pp 159–185
34. Ginsberg SD (2008) Transcriptional profiling of small samples in the central nervous system. Methods Mol Biol 439:147–158
35. Ginsberg SD (2009) Microarray use for the analysis of the CNS. In: Squire LR (ed) Encyclopedia of neuroscience, vol 5. Academic Press, Oxford, pp 835–841
36. Ginsberg SD, Mirnics K (2006) Functional genomic methodologies. Prog Brain Res 158:15–40
37. NTR gene expression in single cholinergic basal forebrain neurons mark the progression of Alzheimer’s disease. J Neurochem 97:475–487
38. Ginsberg SD, Alldred MJ, Counts SE et al (2010a) Microarray analysis of hippocampal CA1 neurons implicates early endosomal dysfunction during Alzheimer’s disease progression. Biol Psychiatry 68:885–893
39. Ginsberg SD, Mufson EJ, Counts SE et al (2010b) Regional selectivity of rab5 and rab7 protein upregulation in mild cognitive impairment and Alzheimer’s disease. J Alzheimers Dis 22:631–639
40. Ginsberg SD, Alldred MJ, Che S (2012) Gene expression levels assessed by CA1 pyramidal neuron and regional hippocampal dissections in Alzheimer’s disease. Neurobiol Dis 45:99–107
41. Granholm AC, Sanders LA, Crnic LS (2000) Loss of cholinergic phenotype in basal forebrain coincides with cognitive decline in a mouse model of Down’s syndrome. Exp Neurol 161:647–663
42. Granholm A-C, Sanders L, Seo H et al (2003) Estrogen alters amyloid precursor protein as well as dendritic and cholinergic markers in a mouse model of Down syndrome. Hippocampus 13:905–914
43. Gygi SP, Rochon Y, Franza BR, Aebersold R (1999) Correlation between protein and mRNA abundance in yeast. Mol Cell Biol 19:1720–1730
44. Hanney M, Prasher V, Williams N et al (2012) Memantine for dementia in adults older than 40 years with Down’s syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial. Lancet 379:528–536
45. Holtzman DM, Santucci D, Kilbridge J et al (1996) Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome. Proc Natl Acad Sci USA 93:13333–13338
46. Howe CL, Mobley WC (2004) Signaling endosome hypothesis: a cellular mechanism for long distance communication. J Neurobiol 58:207–216
47. Huang YZ, McNamara JO (2012) Neuroprotective effects of reactive oxygen species mediated by BDNF-independent activation of TrkB. J Neurosci 32:15521–15532
48. Hunter CL, Isacson O, Nelson M et al (2003) Regional alterations in amyloid precursor protein and nerve growth factor across age in a mouse model of Down’s syndrome. Neurosci Res 45:437–445
49. Hyde LA, Crnic LS (2001) Age-related deficits in context discrimination learning in Ts65Dn mice that model Down syndrome and Alzheimer’s disease. Behav Neurosci 115:1239–1246
50. Ikonomovic MD, Sheffield R, Armstrong DM (1995) AMPA-selective glutamate receptor subtype immunoreactivity in the hippocampal formation of patients with Alzheimer’s disease. Hippocampus 5:469–486
51. Ikonomovic MD, Mizukami K, Davies P et al (1997) The loss of GluR2 (3) immunoreactivity precedes neurofibrillary tangle formation in the entorhinal cortex and hippocampus of Alzheimer brain. J Neuropathol Exp Neurol 56:1018–1027
52. Insausti AM, Megías M, Crespo D et al (1998) Hippocampal volume and neuronal number in Ts65Dn mice: a murine model of Down syndrome. Neurosci Lett 253:175–178
53. Jacobs PA, Hassold TJ (1995) The origin of numerical chromosome abnormalities. Adv Genet 33:101–133
54. Jiang Y, Mullaney KA, Peterhoff CM et al (2010) Alzheimer’s-related endosome dysfunction in Down syndrome is Abeta-independent but requires APP and is reversed by BACE-1 inhibition. Proc Natl Acad Sci USA 107:1630–1635
55. Kaur G, Sharma A, Xu W et al (2014) Glutamatergic transmission aberration: a major cause of behavioral deficits in a murine model of Down’s syndrome. J Neurosci 34:5099–5106
56. Kelley C, Powers B, Velazquez R (2014a) Sex differences in the cholinergic basal forebrain in the Ts65Dn mouse model of Down syndrome and Alzheimer’s disease. Brain Pathol 24:33–44
57. Kelley CM, Powers BE, Velazquez R et al (2014b) Maternal choline supplementation differentially alters the basal forebrain cholinergic system of young-adult Ts65Dn and disomic mice. J Comp Neurol 522:1390–1410
58. Kervern M, Angeli A, Nicole O et al (2012) Selective impairment of some forms of synaptic plasticity by oligomeric amyloid-β peptide in the mouse hippocampus: implication of extrasynaptic NMDA receptors. J Alzheimers Dis 32:183–196
59. Koch G, Di Lorenzo F, Bonnì S et al (2012) Impaired LTP- but not LTD-like cortical plasticity in Alzheimer’s disease patients. J Alzheimers Dis 31:593–599
60. Köhler C, Chan-Palay V, Wu JY (1984) Septal neurons containing glutamic acid decarboxylase immunoreactivity project to the hippocampal region in the rat brain. Anat Embryol (Berl) 169:41–44
61. Kurt MA, Davies DC, Kidd M et al (2000) Synaptic deficit in the temporal cortex of partial trisomy 16 (Ts65Dn) mice. Brain Res 858:191–197
62. Leverenz JB, Raskind MA (1998) Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: a regional quantitative analysis. Exp Neurol 150:296–304
63. Lockrow J, Prakasam A et al (2009) Cholinergic degeneration and memory loss delayed by vitamin E in a Down syndrome mouse model. Exp Neurol 216:278–289
64. Lockrow J, Boger H, Bimonte-Nelson H, Granholm A-C (2011a) Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome. Behav Brain Res 221:610–622
65. Lockrow J, Boger H, Gerhardt G et al (2011b) A noradrenergic lesion exacerbates neurodegeneration in a Down syndrome mouse model. J Alzheimers Dis 23:471–489
66. Lorenzi HA, Reeves RH (2006) Hippocampal hypocellularity in the Ts65Dn mouse originates early in development. Brain Res 1104:153–159
67. Maeder ML, Linder SJ, Cascio VM et al (2013) CRISPR RNA-guided activation of endogenous human genes. Nat Methods 10:977–979
68. Mann DM, Yates PO, Marcyniuk B, Ravindra CR (1986) The topography of plaques and tangles in Down’s syndrome patients of different ages. Neuropathol Appl Neurobiol 12:447–457
69. McCulloch CE, Searle SR, Neuhaus JM (2008) Generalized, linear, and mixed models, 2nd edn. Wiley, New York
70. Middei S, Roberto A, Berretta N et al (2010) Learning discloses abnormal structural and functional plasticity at hippocampal synapses in the APP23 mouse model of Alzheimer’s disease. Learn Mem 17:236–240
71. Moon J, Chen M, Gandhy SU et al (2010) Perinatal choline supplementation improves cognitive functioning and emotion regulation in the Ts65Dn mouse model of Down syndrome. Behav Neurosci 124:346–361
72. Mufson EJ, Counts SE, Fahnestock M, Ginsberg SD (2007) Cholinotrophic molecular substrates of mild cognitive impairment in the elderly. Curr Alzheimer Res 4:340–350
73. + -mediated nitrosative stress in neurodegenerative diseases: possible pharmacological strategies. Cell Calcium 47:190–197
74. Nixon RA, Cataldo AM (2006) Lysosomal system pathways: genes to neurodegeneration in Alzheimer’s disease. J Alzheimers Dis 9:277–289
75. Parker SE, Mai CT, Canfield MA et al (2010) Updated national birth prevalence estimates for selected birth defects in the United States, 2004–2006. Birth Defects Res A Clin Mol Teratol 88:1008–1016
76. Peterson GM, Williams LR, Varon S, Gage FH (1987) Loss of GABAergic neurons in medial septum after fimbria-fornix transection. Neurosci Lett 76:140–144
77. Peterson GM, Lanford GW, Powell EW (1990) Fate of septohippocampal neurons following fimbria-fornix transection: a time course analysis. Brain Res Bull 25:129–137
78. Pollonini G, Gao V, Rabe A, Palminiello S (2008) Abnormal expression of synaptic proteins and neurotrophin-3 in the Down syndrome mouse model Ts65Dn. Neuroscience 156:99–106
79. Proctor DT, Coulson EJ, Dodd PR (2010) Reduction in post-synaptic scaffolding PSD-95 and SAP-102 protein levels in the Alzheimer inferior temporal cortex is correlated with disease pathology. J Alzheimers Dis 21:795–811
80. Rajagopal R, Chen Z-Y, Lee FS, Chao MV (2004) Transactivation of Trk neurotrophin receptors by G-protein-coupled receptor ligands occurs on intracellular membranes. J Neurosci 24:6650–6658
81. Rammes G, Hasenjäger A, Sroka-Saidi K et al (2011) Therapeutic significance of NR2B-containing NMDA receptors and mGluR5 metabotropic glutamate receptors in mediating the synaptotoxic effects of β-amyloid oligomers on long-term potentiation (LTP) in murine hippocampal slices. Neuropharmacology 60:982–990
82. Reeves RH, Irving NG, Moran TH et al (1995) A mouse model for Down syndrome exhibits learning and behaviour deficits. Nat Genet 11:177–184
83. Reisberg B, Doody R, Stöffler A (2003) Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med 348:1333–1341
84. Reisberg B, Doody R, Stoffler A (2006) A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol 63:49–54
85. Rueda N, Llorens-Martín M, Flórez J et al (2010) Memantine normalizes several phenotypic features in the Ts65Dn mouse model of Down syndrome. J Alzheimers Dis 21:277–290
86. Rueda N, Flórez J, Martínez-Cué C (2012) Mouse models of Down syndrome as a tool to unravel the causes of mental disabilities. Neural Plast 2012:584071
87. Salehi A, Delcroix J-D, Belichenko PV et al (2006) Increased App expression in a mouse model of Down’s syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron 51:29–42
88. Saran NG, Pletcher MT, Natale JE et al (2003) Global disruption of the cerebellar transcriptome in a Down syndrome mouse model. Hum Mol Genet 12:2013–2019
89. Shaulsky G, Loomis WF (2002) Gene expression patterns in Dictyostelium using microarrays. Protist 153:93–98
90. Skaper SD (2008) The biology of neurotrophins, signalling pathways, and functional peptide mimetics of neurotrophins and their receptors. CNS Neurol Disord Drug Targets 7:46–62
91. Stempler S, Ruppin E (2012) Analyzing gene expression from whole tissue vs. different cell types reveals the central role of neurons in predicting severity of Alzheimer’s disease. PLoS One 7:e45879
92. Sturgeon X, Gardiner KJ (2011) Transcript catalogs of human chromosome 21 and orthologous chimpanzee and mouse regions. Mamm Genome 22:261–271
93. Talantova M, Sanz-Blasco S, Zhang X et al (2013) Aβ induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. Proc Natl Acad Sci USA 110:E2518–E2527
94. Tuszynski M (2002) Growth-factor gene therapy for neurodegenerative disorders. Lancet Neurol 1:51–57
95. Tuszynski MH (2007) Nerve growth factor gene therapy in Alzheimer disease. Alzheimer Dis Assoc Disord 21:179–189
96. Velazquez R, Ash JA, Powers BE et al (2013) Maternal choline supplementation improves spatial learning and adult hippocampal neurogenesis in the Ts65Dn mouse model of Down syndrome. Neurobiol Dis 58:92–101
97. Wang T, Huang Q, Reiman EM et al (2013) Effect of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia. J Clin Pyschopharmacol 33:636–642
98. Williams R, Chung JY, Ylaya K et al (2010) Characterizations and validations of novel antibodies toward translational research. Proteomics Clin Appl 4:618–625
99. Wisniewski K, Wisniewski H, Wen G (1985) Occurrence of neuropathological changes and dementia of Alzheimer’s disease in Down’s syndrome. Ann Neurol 17:278–282